Can urinary nerve growth factor be a biomarker for overactive bladder?
The clinical diagnosis of overactive bladder (OAB) greatly varies and is based on subjective symptoms. A more objective method to diagnose and assess therapeutic outcome in OAB patients, especially for health care providers not trained in urology, needs to be found. Evidence has shown that urinary proteins such as nerve growth factor (NGF) and prostaglandin E(2) levels increase in patients with OAB, bladder outlet obstruction, and detrusor overactivity. Urinary NGF level increases physiologically in normal subjects at urge to void, but increases pathologically in OAB patients at a small bladder volume and with a sensation of urgency. Recent studies have shown that patients with OAB dry and OAB wet have significantly higher urinary NGF levels compared with control groups and patients with increased bladder sensation. Urinary NGF levels decrease after antimuscarinic therapy and further decrease after detrusor botulinum toxin injections in refractory OAB. Urinary NGF level could be a potential biomarker for diagnosis of OAB and assessment of the therapeutic effect of antimuscarinic therapy. The latest medical advances in this field are reviewed herein.
Kuo
Hann-Chorng
HC
Liu
Hsin-Tzu
HT
Chancellor
Michael B
MB
BJU Int. 2008 Nov;102(10):1440-4
18489524
J Neurosci. 2006 Oct 18;26(42):10847-55
17050722
Urology. 2008 Jul;72(1):104-8; discussion 108
18400272
J Urol. 2006 Jan;175(1):191-4; discussion 194-5
16406907
J Urol. 2006 Jul;176(1):177-85
16753396
Neurourol Urodyn. 2001;20(3):249-57
11385691
Rev Urol. 2002;4 Suppl 4:S7-S18
16986023
Prog Brain Res. 2006;152:245-63
16198705
Am J Pathol. 1999 Oct;155(4):1183-93
10514401
Eur Urol. 2006 Aug;50(2):333-8
16713066
Nat Clin Pract Urol. 2006 Feb;3(2):101-10
16470209
J Urol. 2001 Sep;166(3):1111-8
11490308
J Urol. 2005 Aug;174(2):604-7
16006914
J Urol. 2006 Jun;175(6):2341-4
16697870
J Pain. 2004 Apr;5(3):150-6
15106127
Urology. 2005 Jul;66(1):94-8
15992869
J Urol. 2005 Sep;174(3):984-9
16094019
J Urol. 2005 Sep;174(3):977-82; discussion 982-3
16094018
Eur Urol. 2006 Oct;50(4):684-709; discussion 709-10
16934391
Urology. 2007 Sep;70(3):463-8
17905097
Prog Brain Res. 2006;152:97-115
16198696
Eur Urol. 2004 Apr;45(4):510-5
15041117
J Urol. 2001 Aug;166(2):550-2; discussion 553
11458066
J Urol. 2008 Jun;179(6):2270-4
18423678
BMC Physiol. 2007 Aug 28;7:9
17725832
J Urol. 2002 Nov;168(5):2269-74
12394773
Prog Neurobiol. 1999 Apr;57(6):583-606
10221783
J Clin Invest. 1991 Nov;88(5):1709-15
1939656
Neurourol Urodyn. 2007;26(3):405-9
17266135
Eur Urol. 2006 Apr;49(4):644-50
16426734
BJU Int. 2003 Nov;92(7):731-5
14616456
J Auton Nerv Syst. 1994 Oct;49(2):147-58
7806767
Br J Urol. 1997 Apr;79(4):572-7
9126085
Am J Physiol. 1999 Sep;277(3):R786-94
10484496
Neurourol Urodyn. 2003;22(7):638-42
14595606
Urology. 2004 May;63(5):868-72
15134967
Am J Obstet Gynecol. 2005 May;192(5):1735-40
15902187
J Urol. 1997 Feb;157(2):600-3
8996367
Eur Urol. 2009 Oct;56(4):700-6
18472208
Am J Manag Care. 2000 Jul;6(11 Suppl):S580-90
11183901
Exp Neurol. 2000 Jan;161(1):273-84
10683293
BJU Int. 2007 Jun;99(6):1439-42
17419703
Obstet Gynecol. 2004 Dec;104(6):1263-9
15572487
Neurourol Urodyn. 2008;27(5):417-20
17924444
Neurourol Urodyn. 2003;22(2):105-8
12579626
J Urol. 2006 May;175(5):1773-6; discussion 1776
16600756
BJU Int. 2009 Jun;103(12):1668-72
19220267
J Urol. 2004 Jan;171(1):478-82
14665959
J Urol. 1999 Feb;161(2):438-41; discussion 441-2
9915421